Last updated on September 2017

Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Who Have an Inadequate Response to Eculizumab


Brief description of study

The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have an inadequate response to eculizumab. Patients will be treated with RA101495 for 12 weeks.

Clinical Study Identifier: NCT03030183

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Sponsor: Ra Pharmaceuticals, Inc.

Investigative Site
Duarte, CA United States
  Connect »

Sponsor: Ra Pharmaceuticals, Inc.

Investigative Site
Los Angeles, CA United States
  Connect »

Sponsor: Ra Pharmaceuticals, Inc.

Investigative Site
Chicago, IL United States
  Connect »

Sponsor: Ra Pharmaceuticals, Inc.

Investigative Site
Manhasset, NY United States
  Connect »

Sponsor: Ra Pharmaceuticals, Inc.

Investigative Site
Durham, NC United States
  Connect »

Sponsor: Ra Pharmaceuticals, Inc.

Investigative Site
Dallas, TX United States
  Connect »